Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma (Q70987363)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8595540%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

title

Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8595540%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

1 reference

Bousquet J

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8595540%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

Aubert B

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8595540%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

Bons J

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8595540%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

publication date

1 February 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8595540%20AND%20SRC:MED&resulttype=core&format=json

Annals of Allergy, Asthma & Immunology

15 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8595540%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

volume

76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8595540%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8595540%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

page(s)

189-194

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8595540%20AND%20SRC:MED&resulttype=core&format=json

Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients

15 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Cromolyn sodium is effective in adult chronic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Evaluation of the addition of cromolyn sodium to bronchodilator maintenance therapy in the long-term management of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Are there any detrimental effects of the use of inhaled long-acting beta 2-agonists in the treatment of asthma?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Long- versus short-acting beta 2-agonists. Implications for drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Regular inhaled beta-agonist treatment in bronchial asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Risks versus benefits of inhaled beta 2-agonists in the management of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

The use of beta-agonists and the risk of death and near death from asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Efficacy and safety of salmeterol in childhood asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Nedocromil sodium and sodium cromoglycate in patients aged over 50 years with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Comparison of dose-response effects of inhaled beclomethasone dipropionate and budesonide in the management of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

Aerosol beclomethasone dipropionate: a dose-response study in chronic bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963421-7

7 January 2021

10.1016/S1081-1206(10)63421-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8595540%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

1 reference